Skip to main content

Advertisement

Log in

The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAM-containing regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3%) in the CAM group and 11 patients (84.6%) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The long-term results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1–S25.

    Google Scholar 

  2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.

    Article  PubMed  CAS  Google Scholar 

  3. McGrath EE, McCabe J, Anderson PB. American Thoracic Society; Infectious Diseases Society of America. Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Pract. 2008;62:1947–55.

    Article  PubMed  CAS  Google Scholar 

  4. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med. 1996;153:1766–72.

    PubMed  Google Scholar 

  5. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 2001;32:1547–53.

    Article  PubMed  CAS  Google Scholar 

  6. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866–72.

    PubMed  CAS  Google Scholar 

  7. Corpe RF. Surgical management of pulmonary disease due to Mycobacterium aviumintracellulare. Rev Infect Dis. 1981;3:1064–7.

    Article  PubMed  CAS  Google Scholar 

  8. Moran JF, Alexander LG, Stauh EW, Young WG, Sealy WC. Long-term results of pulmonary resection for atypical mycobacterial disease. Am Thorac Surg. 1983;35:597–604.

    Article  CAS  Google Scholar 

  9. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12:195–202.

    Article  PubMed  CAS  Google Scholar 

  10. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130–8.

    Article  PubMed  Google Scholar 

  11. Wallace RJ Jr, Nash DR, Steele LC, Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol. 1986;24:976–81.

    PubMed  CAS  Google Scholar 

  12. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352–61.

    Article  PubMed  CAS  Google Scholar 

  13. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother. 2003;47:2442–4.

    Article  PubMed  CAS  Google Scholar 

  14. Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011;37:296–301.

    Article  PubMed  CAS  Google Scholar 

  15. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother. 2007;51:4071–6.

    Article  PubMed  CAS  Google Scholar 

  16. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis. 2003;187:1977–80.

    Article  PubMed  CAS  Google Scholar 

  17. Horiguchi T, Kondo R, Miyazaki J, Shiga M, Sugiyama M, Handa M, Munekata E. Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium–intracellulare complex infection. J Int Med Res. 2004;32:530–9.

    PubMed  CAS  Google Scholar 

  18. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63:627–34.

    Article  PubMed  CAS  Google Scholar 

  19. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al. Initial clarithromycin monotherapy for Mycobacterium aviumintracellulare complex lung disease. Am J Respir Crit Care Med. 1994;149:1335–41.

    PubMed  Google Scholar 

  20. Dautzenberg B, Piperno D, Diot P, Trufot-Pernot C, Chauvin JP. Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium patients without AIDS. Chest. 1995;107:1035–40.

    Article  PubMed  CAS  Google Scholar 

  21. Iseman MD. Medical management of pulmonary diseases caused by Mycobacterium avium complex. Clin Chest Med. 2002;23:633–41.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We appreciate the assistance of Dr. Brian Quinn for editing the English in this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masaki Fujita.

About this article

Cite this article

Fujita, M., Kajiki, A., Tao, Y. et al. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. J Infect Chemother 18, 146–151 (2012). https://doi.org/10.1007/s10156-011-0303-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-011-0303-5

Keywords

Navigation